Last edition
News about "Biocon Biologics"
Biocon Biologics' Report Offers Insights on Increasing Biosimilars Adoption in LMICs
Biocon Biologics commissioned the study, defined the methodology and collaborated with Clarivate to develop the final report.
Biocon Biologics | 09/10/2024 | By Aishwarya
Biocon Biologics Signs License Deal with Janssen for Bmab 1200
Under the terms of this settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan. Regulatory filings in these markets are currently under review.
Biocon Biologics | 29/08/2024 | By Aishwarya
Biocon Biologics Gets EMA Approval for Bevacizumab and its New mAbs Facility in India
Biocon Biologics Ltd. has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new, world-class, multi-product monoclonal antibodies (mAbs) drug substance facility in Bengaluru.
Biocon Biologics | 24/06/2024 | By Aishwarya | 344
Biocon Biologics Gets FDA Approval for Biosimilar Aflibercept for Yesafili
Biocon Biologics Ltd (BBL) has announced that the US Food and Drug Administration (US FDA) has approved the company’s first-to-file application for Yesafili.
Biocon Biologics | 21/05/2024 | By Aishwarya | 101
Eris Lifesciences Announces Acquisition of Biocon Biologics
Eris Lifesciences Ltd. has recently acquired Biocon Biologics’ Branded Formulations business in India in a deal worth INR 1,242 crore.
Biocon Biologics | 19/03/2024 | By Manvi | 151
Biocon gets 8 observations from USFDA after inspection of Malaysia insulins facility
Biocon gets 8 observations from USFDA after inspection of Malaysia insulins facility
Biocon Biologics | 25/07/2023 | By Sudeep Soparkar | 289
Biocon Biologics mAbs facility bags EU GMP Certification for bBevacizumab
The approval reflects Biocon Biologics’ compliance with the highest international regulatory standards
Biocon Biologics | 02/05/2023 | By Sudeep Soparkar | 292
Biocon Biologics appoints Shreehas Tambe as MD and CEO
Tambe has shaped and grown the company's biosimilars business
Biocon Biologics | 06/12/2022 | By Sudeep Soparkar | 329
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy